Role of bilirubin in the prognosis of coronary artery disease and its relationship with cardiovascular risk factors: a meta-analysis

Xiao-ling Li†, Cun-rui Zhao‡, Chen-liang Pan, Gaxue Jiang and Bo Zhang*

Abstract

Background: Bilirubin is a heme catabolism product with antioxidant, anti-inflammatory, and anti-apoptotic properties and is implicated in the prognosis of several diseases. This study evaluates the prognostic role of bilirubin in coronary artery disease (CAD) patients.

Methods: After identifying studies from the literature, meta-analyses were performed to achieve a) overall estimates of serum total bilirubin levels in patients with myocardial infarction (MI), non-MI CAD and healthy individuals; b) odds ratios (OR) of adverse outcomes between higher and lower total bilirubin levels; c) standardized mean difference (SMD) in total bilirubin levels in patients with high vs low CAD severity; and d) correlation between disease severity and total bilirubin. Metaregression analyses were performed to examine the relationship between cardiovascular risk factors and increasing quartiles of total bilirubin levels.

Results: Forty-three studies were identified. Pooled serum total bilirubin levels were 0.72 mg/dl [95% confidence interval (CI): 0.60, 0.83] in MI patients; 0.65 mg/dl [95% CI: 0.60, 0.69] in non-MI CAD patients; and 0.66 mg/dl [95% CI: 0.56, 0.75] in healthy individuals. Higher total bilirubin levels were associated with greater odds of adverse outcomes in MI patients (OR: 1.08 [95% CI: 0.99, 1.18]) but lower odds in non-MI CAD patients (OR: 0.80 [95% CI: 0.73, 0.88]). Compared to non-severe cases, total bilirubin levels were higher in patients with severe MI (SMD 0.96 [95% CI: −0.10, 2.01]; p = 0.074) but were lower in severe non-MI CAD patients (SMD −0.30 [95% CI: −0.56, −0.03]; p = 0.02). Total bilirubin levels correlated positively with MI severity (r = 0.41 [95% CI: 0.24, 0.59]; p < 0.01) but correlated negatively with non-MI CAD severity (r = −0.17 [95% CI: −0.48, 0.14]; p = 0.28). Female sex was inversely associated with increasing quartiles of bilirubin (meta-regression coefficient: −8.164 [−14.531, −1.769]; p = 0.016) in MI patients.

Conclusion: Prognostic role of bilirubin for CAD appears complicated, as different odds are observed for MI and non-MI CAD patients which weakens the case of causal involvement of bilirubin in CAD etiology or prognosis.

Keywords: Coronary heart disease, Bilirubin, Prognosis

Introduction

Coronary artery disease (CAD) is the most common heart disease. It is an atherosclerotic disease in which blood flow is impeded in the coronary arteries due to the formation and deposition of plaque on the vessel wall that can lead to angina, myocardial infarction (MI), or sudden death [1–3]. The prevalence of CAD in the general population is estimated to be 6.3% and is less in women (5.2%).
than in men (7.5%) [4]. The correlation between the prevalence of CAD and the human development index is negative in developed countries ($r = -0.34$) but positive in developing countries ($r = 0.47$) [4]. CAD burden is increasing in low-income and middle-income countries [5]. However, low education and socioeconomic status increase the odds of CAD even in developed countries [6]. Risk factors for the development of CAD include later age, male sex, diabetes mellitus, hypertension, smoking, dyslipidemia, obesity, homocystinuria, renal dysfunction, sedentary lifestyle, unhealthy diet, and family history/ genetics [3, 7–11].

Bilirubin is a heme degradation product. During the catabolism of hemoglobin, heme is converted into biliverdin by heme oxygenase which is acted upon by biliverdin reductase to form bilirubin. In liver cells, bilirubin is changed to a conjugated form for secretion in bile juice [12]. At concentrations found in human plasma, bilirubin acts as an antioxidant to scavenge peroxyl radicals as efficiently as alpha-tocopherol [13, 14]. Both free and bound forms of bilirubin can inhibit the oxidation of low-density lipoproteins at physiological concentrations [15, 16]. Oxidation of low-density lipoproteins is an important initial step in atherogenesis that can stimulate platelet aggregation and can alter vasomotor properties [14]. Gilbert’s syndrome patients have a reduced risk of cardiovascular disease (CVD) which is associated with increased bilirubin levels and altered lipid and inflammatory profiles [17]. At pathological levels, unconjugated bilirubin inhibits cytotoxic T cell activity and proliferative responses to human peripheral blood mononuclear cells in patients with neonatal or obstructive jaundice [18].

Research conducted during the last few decades has revealed that bilirubin may have a role in the prognosis of CAD. An inverse relationship was reported between serum bilirubin levels and atherosclerosis [19] and higher serum bilirubin levels were found to be associated with a better prognosis in patients with arteriosclerotic diseases [20]. Another meta-analysis found a U-shaped curve to depict the relationship between total bilirubin levels and CAD [21]. However, whereas elevated total bilirubin levels (within physiological limits) are reported to be associated with a lower risk of first MI [22], in patients with MI, a positive relationship is found between serum bilirubin levels and major adverse cardiovascular events (MACE) [23]. These observations provide an impetus for a review of studies that sought the associations between bilirubin levels and the prognosis of CAD. The objective of the present study was to conduct a systematic review of studies that investigated the bilirubin levels in CAD patients and sought the associations between bilirubin levels and disease severity in MI and non-MI CAD patients and to perform meta-analyses of important statistical indices.

**Methods**

The present study was performed by following PRISMA guidelines [24].

**Eligibility**

Inclusion criteria were: a study recruited patients with CAD to evaluate the prognostic role of bilirubin in MI and non-MI CAD patients and reported (a) bilirubin levels; (b) odds ratios of adverse outcomes between higher and lower bilirubin levels; and (c) correlations between bilirubin levels and disease severity. Studies were excluded if reported (a) the associations between bilirubin and non-cardiovascular complications; (b) non-prognostic associations; (c) associational point estimate/s other than odds ratios; and (d) the changes in bilirubin levels after MI or coronary intervention.

**Literature search**

A literature survey was conducted in the Google Scholar, PubMed, Ovid, and Science Direct databases using the most relevant keywords including coronary artery disease, CAD, coronary heart disease, CHD, acute coronary syndrome, ACS, ischemic heart disease, IHD, angina, myocardial infarction, MI, percutaneous coronary intervention, PCI, bilirubin, prognosis, prognostic, association, and correlation. Literature search strategy is presented in Appendix S1. References lists of important research and review articles were also screened. The literature search encompassed original articles published in English from the date of database inception until March 2022. Two reviewers screened the records independently and then merged their listings. Study selection was carried out with mutual consultations and if any disagreement appeared, a third reviewer was involved.

**Data analyses**

Demographic and clinical data, prevalent conditions, medications, lipid profiles, liver function data, CVD risk factor data, and statistical endpoints were extracted from the research articles of respective eligible studies and were organized on data sheets. Two reviewers extracted data from research articles independently and then unified output with mutual consultation. Quality assessment of the included studies was performed with Newcastle–Ottawa Scale for Observational Studies [25] and publication bias assessment was performed with Begg’s rank correlation test [26].

Total bilirubin levels reported by the individual studies were pooled using the DerSimonian-Laird method in patients with MI and non-MI CAD and in healthy individuals. Random-effects meta-analyses of standardized mean difference (SMD) was performed to assess the significance of difference in total bilirubin levels in patients...
with high vs low CAD severity. Odds ratios (ORs) of adverse outcomes between higher and lower total bilirubin levels in CAD patients reported by the individual studies were pooled using the DerSimonian-Laird method [27]. Subgroup analyses were performed by categorizing MI and non-MI CAD patients.

A meta-analysis of correlation coefficients was performed under the random-effects model to estimate the correlation between total bilirubin levels and disease severity. For this meta-analysis, correlation coefficient values were first converted to Fisher’s z-scores and their respective standard errors were derived from the sample sizes. Meta-analysis outcomes were back-transformed to correlation coefficients.

To seek linear relationships between the increasing quantiles of total bilirubin and several explanatory variables, meta-regression analyses were performed using the restricted maximum likelihood method. Explanatory variables were the age, sex, body mass index, hypertension, dyslipidemia, diabetes mellitus, smoking, CVD history, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, hemoglobin, high-sensitivity c-reactive protein, serum creatinine, alanine transaminase, aspartate transaminase, gamma-glutamyl transaminase, alkaline phosphatase, statin use, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker use, calcium channel blocker use, and beta-blockers use.

The statistical index used to estimate heterogeneity was $I^2$ which assesses between-study inconsistency in the outcomes. It informs what proportion of the observed variance reflects differences in true effect sizes rather than sampling error [28]. Begg’s rank correlation test was performed for the assessment of publication bias. All statistical analyses were performed with Stata software (version 12; Stata Corporation, College Station, Texas, USA).

Results
Forty-three studies [29–71] were included (Fig. 1). In these studies, 34,976 patients with CAD and 29,229 non-CAD individuals from general populations were recruited. The important characteristics of the included studies are presented in Table 1. There was no significant publication bias according to the Begg’s test (adjusted Kendall’s score: $-20 \pm 86$; $p=0.816$; Figure S1). The quality of the included studies was generally moderate to high (Table S1).

In the pooled analysis, serum total bilirubin levels were 0.72 mg/dl [95% confidence interval (CI): 0.60, 0.83] in MI patients; 0.65 mg/dl [95% CI: 0.60, 0.69] in non-MI CAD patients; and 0.66 mg/dl [95% CI: 0.56, 0.75] in healthy individuals from general populations (Fig. 2).

A pooled analysis of the odds ratios reported by the individual studies found higher odds of adverse outcomes with higher total bilirubin levels in MI patients (OR: 1.08 [95% CI: 0.99, 1.18]) but lower odds with higher total bilirubin levels in non-MI CAD patients (OR: 0.80 [95% CI: 0.73, 0.88]; Fig. 3).

A meta-analysis of SMD in bilirubin levels between higher and lower disease severity indices found statistically non-significantly higher total bilirubin levels in patients with severe MI (SMD 0.96 [95% CI: −0.095, 2.01]; $p=0.074$) but significantly lower total bilirubin levels in patients with severe non-MI CAD (SMD −0.30 [$−0.56, −0.03$]; $p=0.02$; Fig. 4).

In a meta-analysis of correlation coefficients, total bilirubin levels were significantly positively correlated with MI severity ($r=0.41$ [95% CI: 0.24, 0.59]; $p<0.01$) but were non-significantly inversely correlated with non-MI CAD severity ($r=−0.17$ [95% CI: −0.48, 0.14]; $p=0.28$; Fig. 5).

The female sex was significantly inversely associated with increasing quantiles of total bilirubin ($−8.16$ [$−14.53, −1.77$]; $p=0.016$) in MI patients. In MI patients, hemoglobin levels were positively associated with increasing quantiles of total bilirubin. None of the cardiovascular risk factors tested had a significant relationship with increasing total bilirubin quantiles (Table 2).

Discussion
This meta-analysis has found that bilirubin may have differing roles for MI and non-MI CAD patients as a) higher total bilirubin levels were associated with higher odds in MI patients but lower odds in non-MI CAD patients; b) total bilirubin levels were higher in severe MI patients but lower in severe non-MI CAD patients; and c) total bilirubin levels correlated positively with MI severity but correlated inversely with non-MI CAD severity. Thus, in general, higher bilirubin levels predicted poor outcomes in MI patients but better outcomes in non-MI CAD patients.

These outcomes are consistent with previously published meta-analyses on this topic. A meta-analysis found an inverse relationship between serum bilirubin levels and atherosclerosis in men [19]. Another meta-analysis has also reported a better prognosis for patients with arteriosclerotic diseases having higher serum total bilirubin levels [20]. Moreover, a meta-analysis found that higher bilirubin levels were associated with a reduced risk of first MI incidence [22]. On the other hand, meta-analyses have found a positive relationship between bilirubin levels and the incidence of MACE in patients with MI [22, 23].
In the third National Health and Nutrition Examination Survey (NHANES) that included 176,748,462 individuals from the general population, the serum bilirubin levels of the participants were 0.62 [0.61, 0.63] mg/dl [72]. This estimate is comparable to our pooled analysis that found serum total bilirubin levels to be 0.66 mg/dl [0.56, 0.75] in the general population. In NHANES survey, females had significantly lower bilirubin levels (0.52 vs 0.72 mg/dl) [72]. We have found an inverse relationship between the female percentage and increasing quantiles of bilirubin. Females may be more prone to adverse outcomes of CAD. A higher risk of MI or 1-month mortality is observed for women who underwent a coronary intervention [73, 74]. Women with CAD are also more vulnerable to the effects of diabetes [75, 76].

In the present study, it was not possible to perform a direct comparison of bilirubin levels between MI and non-MI CAD patients. In the pooled analysis, bilirubin levels did not differ appreciably between patients with MI, non-MI CAD, or healthy individuals. Importantly, high statistical heterogeneity observed in these analyses indicates wide variations within these three groups. Huang et al. [43] found significantly higher bilirubin levels in patients with MI in comparison with non-MI CAD patients. It has been reported that increased bilirubin levels decrease after the acute phase of MI [77].
Chung et al. [35] who found higher bilirubin levels to predict a worse prognosis in the acute phase of MI, did not find this one year after infarction, which coincides with the observation that heme oxygenase-1 (HO-1) activation is restricted to the acute phase only [77]. HO-1 is a rate-limiting enzyme. A strong correlation
is observed between HO-1 activation and increased bilirubin levels in patients with MI or those undergoing percutaneous coronary intervention. However, the existence of HO-1 gene polymorphism in humans manifests inter-individual differences in the response of HO-1 to stress [78].

Currently, the precise role of bilirubin in the pathogenesis or prevention of CAD is not clear. Being an antioxidant, anti-apoptotic, and anti-inflammatory compound, it may participate in protecting or slowing the progression of atherosclerosis [71]. However, as observed in the present study, bilirubin offers a poor prognosis for MI but a good prognosis for non-MI CAD complicates the conceived role of bilirubin. It may be possible that adverse outcomes arising from the infarction itself may get associated with bilirubin which increases in
such stressful events to reduce the harm but is unable to compensate for the overwhelming detrimental effects of infarction [65]. A U-shaped curve observed by many authors [50, 59, 79] to represent the relationship between the increasing quantiles of bilirubin levels and cardiovascular risk may also support this notion, as the highest bilirubin quantile may reflect acute stress-activated HO-1 activity.

Bilirubin is also found to show inverse relationships with several other diseases including diabetes, peripheral artery disease, Crohn’s disease, systemic lupus erythematosus, schizophrenia, and colorectal cancer [80]. Despite significant associations of bilirubin with cardiovascular outcomes observed in many studies, it is still not clear whether bilirubin has a true prognostic role or acts merely as a marker of disease. Mendelian randomization studies of UGT1A1 polymorphism associated with increased bilirubin levels found no association of bilirubin with stroke and CVD but found a negative association with type 2 diabetes [81, 82].

Present-day evidence on the role of bilirubin in the prognosis of CAD is also constrained by the use of non-standardized estimation methods, and reference values not tailored for sex, ethnicity, and age [80]. Whereas studies have shown that physiologically higher bilirubin levels predict better prognosis in non-MI CAD patients, this is not the case once MI develops. Our study further finds that the odds of an adverse outcome are higher with higher bilirubin levels in MI patients. Thus, more research is required to evaluate the role of bilirubin in non-MI and MI CAD patients and to clarify whether bilirubin has a real prognostic role or represents an epiphenomenon.

Differentiation of MI and non-MI CAD patients for meta-analyses is a strength of the present study. However, some limitations are also associated with this review. High statistical heterogeneity observed in many meta-analyses is an important consideration. Metaregression analyses did not indicate much about the sources of heterogeneity ($I^2$). Other factors might had affected

![Fig. 3](Fig)

A forest graph showing the pooled estimates of odds ratios of adverse outcomes between higher and lower bilirubin levels in MI and non-MI CAD patients. Abbreviations: HFpEF, Heart failure with preserved ejection fraction; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention.
### Fig. 4
A forest graph showing the outcomes of a meta-analysis of standardized mean difference (SMD) in bilirubin levels between higher and lower disease severity indices.

| Study ID | Standardized mean difference (95% CI) | Weight |
|----------|--------------------------------------|--------|
| non-MI CAD |
| Agrawal 2015 | -0.60 (-0.67, -0.33) | 25.17 |
| Erkan 2013 | 0.00 (-0.33, 0.33) | 22.24 |
| Schwertner 1994 | -0.13 (-0.34, 0.08) | 28.02 |
| Turfan 2012 | -0.44 (-0.72, -0.16) | 24.57 |
| Subtotal (I² = 74.1%, p = 0.009) | -0.30 (-0.56, -0.03) | 100.00 |
| MI |
| Hamur 2016 | 2.21 (1.88, 2.55) | 32.94 |
| Kaya 2014 | 0.32 (0.12, 0.53) | 33.66 |
| Sahin 2012 | 0.36 (0.10, 0.61) | 33.40 |
| Subtotal (I² = 98.0%, p = 0.000) | 0.96 (-0.09, 2.01) | 100.00 |

**NOTE:** Weights are from random effects analysis.

### Fig. 5
A forest graph showing the outcomes of a meta-analysis of z-scores of correlation coefficients between disease severity and bilirubin levels.

| Study ID | z-score (95% CI) | Weight |
|----------|------------------|--------|
| MI |
| Acet 2014 | Gensini score | 0.25 (0.15, 0.35) | 33.55 |
| Kaya 2014 | Syntax score | 0.54 (0.44, 0.64) | 33.97 |
| Sahin 2012 | Syntax score | 0.45 (0.33, 0.57) | 32.48 |
| Subtotal (I² = 87.9%, p = 0.000) | 0.41 (0.24, 0.59) | 100.00 |
| Non-MI CAD |
| Akboga 2015 | Gensini score | -0.17 (-0.23, -0.12) | 34.02 |
| Erkan 2013 | Gensini score | 0.16 (0.05, 0.27) | 32.89 |
| Yu 2017 | Syntax score | -0.50 (-0.60, -0.39) | 33.10 |
| Subtotal (I² = 97.1%, p = 0.000) | -0.17 (-0.48, 0.14) | 100.00 |

**NOTE:** Weights are from random effects analysis.
the heterogeneity e.g., HO-1 gene polymorphism causes inter-individual differences in the response of HO-1 to stress [78]. Another important limitation was the inclusion of a smaller number of studies in the meta-analysis of SMD in bilirubin levels between lower and higher disease severity as well as in the meta-analysis of correlation coefficients between bilirubin levels and disease severity.

**Conclusion**

This study found that higher bilirubin levels may predict the outcomes differently in non-MI CAD patients and MI patients as the odds of adverse outcomes with higher bilirubin levels were lower in non-MI CAD patients but were higher in MI patients. Moreover, bilirubin levels were lower in severe non-MI CAD patients but were higher in severe MI patients, and bilirubin levels correlated positively with MI severity but negatively with non-MI CAD severity. However, the presence of high statistical heterogeneity in most of the analyses warrants further studies with the power to delineate confounders to clarify the observed relationships of bilirubin with MI and non-MI CAD prognosis.

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s12872-022-02899-w](https://doi.org/10.1186/s12872-022-02899-w).

**Additional file 1.** PRISMA_checklist.

**Additional file 2: Table S1.** Quality assessment of the included study with Newcastle-Ottawa Quality Assessment Scale. Figure S1. A funnel plot showing the outcomes of Begg’s test. Appendix S1. Literature search strategy.

**Acknowledgements**

Not applicable

**Authors’ contributions**

XLL, CRZ, BZ conceived the study. CLP, GXJ, BZ collected data and data analysis. XLL, CRZ wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

All relevant data specific to the present study are available with corresponding author.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Table 2** Relationship (metaregression coefficient [95% CI]) of CAD prognostic factors with increasing quantiles of bilirubin

| Factor                      | Non-MI CAD                    | MI                          |
|-----------------------------|-------------------------------|-----------------------------|
| Age                         | 0.174 [1.148, 1.496], p = 0.789 | -0.488 [-2.832, 1.856], p = 0.658 |
| Females (%)                 | -2.450 [-11.350, 6.431], p = 0.577 | -8.164 [-14.531, -1.769], p = 0.016 |
| Body mass index             | 0.058 [-0.398, 0.519], p = 0.797 | -1.213 [-5.604, 3.178], p = 0.444 |
| Hypertension (%)            | -0.966 [-8.020, 6.088], p = 0.781 | -1.261 [-10.397, 7.874], p = 0.772 |
| Dyslipidemia (%)            | -1.682 [-8.649, 5.284], p = 0.619 | -2.629 [-25.826, 20.567], p = 0.809 |
| Diabetes mellitus (%)       | -1.613 [-5.935, 2.707], p = 0.451 | 1.637 [-11.572, 14.846], p = 0.794 |
| Smoking (%)                 | -1.421 [-6.014, 3.172], p = 0.533 | -0.709 [-7.872, 6.455], p = 0.835 |
| CVD history (%)             | -1.210 [-5.969, 3.550], p = 0.590 | -0.290 [-4.775, 4.194], p = 0.883 |
| Total cholesterol           | -1.582 [-17.828, 14.663], p = 0.837 | 4.785 [-18.340, 27.909], p = 0.640 |
| Triglycerides               | -5.881 [-25.141, 13.379], p = 0.532 | 3-7.247 [85.008, 70.513], p = 0.827 |
| High-density lipoprotein    | 1.550 [-2.562, 5.663], p = 0.442 | -0.711 [-23.041, 21.620], p = 0.940 |
| Low-density lipoprotein     | 0.991 [-6.170, 8.154], p = 0.776 | -0.809 [-3.912, 2.294], p = 0.586 |
| Hemoglobin                  | 0.532 [0.103, 0.961], p = 0.023 | 0.012 [-0.050, 0.074], p = 0.668 |
| Serum creatinine            | 0.032 [-0.062, 0.126], p = 0.472 | 0.012 [-0.050, 0.074], p = 0.668 |
| c-reactive protein          | -0.014 [-0.411, 0.385], p = 0.939 | 0.676 [-0.844, 2.196], p = 0.285 |
| Alanine transaminase        | 0.740 [-0.959, 2.458], p = 0.371 | 4.411 [-19.875, 28.698], p = 0.60 |
| Aspartate transaminase      | 0.737 [-0.989, 2.463], p = 0.384 | 27.278 [-21.803, 76.359], p = 0.178 |
| γ-glutamyltranspeptidase     | 3.204 [-4.485, 10.892], p = 0.347 | 4.785 [-18.340, 27.909], p = 0.640 |
| Alkaline phosphatase        | 3.433 [-1.669, 8.536], p = 0.162 | 3-7.247 [85.008, 70.513], p = 0.827 |
| Statin use (%)              | -6.804 [-20.256, 6.647], p = 0.305 | -0.711 [-23.041, 21.620], p = 0.940 |
| ACEi/ARB use (%)            | -0.905 [-10.049, 8.239], p = 0.832 | -0.809 [-3.912, 2.294], p = 0.586 |
| Calcium channel blockers (%)| -2.829 [-17.783, 12.125], p = 0.647 | -0.290 [-4.775, 4.194], p = 0.883 |
| Beta blockers use (%)       | -6.034 [-20.581, 8.512], p = 0.394 | 4.785 [-18.340, 27.909], p = 0.640 |

**Table 2** Relationship (metaregression coefficient [95% CI]) of CAD prognostic factors with increasing quantiles of bilirubin
1. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366(1):54–63.
2. Matsuzawa Y, Lerman A. Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis. 2014;25(8):713–24.
3. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18(6):331–44.
4. Zhu KF, Wang YM, Zhou JZ, Zhou QY, Wang NF. National prevalence of coronary heart disease and its relationship with human development index: a systematic review. Eur J Prev Cardiol. 2016;23(S1):S30–43.
5. Gaziano TA, Brton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010;35(2):72–115.
6. Diez-Roux AV, Nieto FJ, Tyroler HA, Crum LD, Szklo M. Social inequalities and atherosclerosis. The atherosclerosis risk in communities study. Am J Epidemiol. 1995;141(10):960–72.
7. Tanaka T, Seto S, Yamamoto K, Kondo M, Otomo T. An assessment of risk disease assessed using CAD-RADS classification: a cross-sectional study in Romanian population. BMJ Open. 2020;10(1):e031799. https://doi.org/10.1136/bmjopen-2019-031799.
8. Canpolat U, Aytemir K, Yorgun H, Hazırolan T, Kaya EB, Şahiner L, et al. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812–23.
9. Popa LE, Petresc B, Cătană C, Moldovanu CG, Feier DS, Lebovici A, et al. Association between cardiovascular risk factors and coronary artery disease assessed using CAD-RADS classification: a cross-sectional study in Romanian population. BMJ Open. 2020;10(1):e031799. https://doi.org/10.1136/bmjopen-2019-031799.
10. Gupta N, Singh T, Chaudhary R, Garg SK, Sandhu GS, Mittal V, et al. Bilirubin in coronary artery disease: cytotoxic or protective? World J Gastrointest Pharmacol Ther. 2016;7(4):469–76.
11. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA. 1987;84(16):5918–22.
12. Nezuil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem. 1994;269(24):16712–9.
13. Hulea SA, Wasowicz E, Kummerow FA. Inhibition of metal-catalyzed oxidation of low-density lipoprotein by free and albumin-bound bilirubin. Biochim Biophys Acta. 1995;1259(1):29–38.
14. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low-density lipoprotein by unconjugated and conjugated bilirubins. Biochim Pharmacol. 1996;51(6):859–62.
15. Wallner M, Marculescu R, Droberer D, Wolz M, Wagner O, Vitek L, et al. Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert’s syndrome. Clin Sci (Lond). 2013;125(5):257–64.
16. Haga Y, Temporo MA, Zetterman RK. Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. Biochim Biophys Acta. 1996;1317(1):65–70.
17. Novotny J, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228(5):568–71.
18. Lan Y, Liu H, Liu J, Zhao H, Wang H. Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis. Medicine. 2019;88(42):e17544. https://doi.org/10.1097/MD.0000000000017544.
19. Zuo L, Huang J, Zhang H, Huang B, Wu X, Chen L, et al. Dose-response association between bilirubin and cardiovascular disease: a systematic review and meta-analysis. Angiology. 2022;11:33197211059693. https://doi.org/10.1177/00033197211059693.
20. Yoo ME, Su MY, Huang Y, Chen W. Physiologically increased total bilirubin is associated with reduced risk of first myocardial infarction: a meta-analysis and dose-response analysis. Nutr Metab Cardiovasc Dis. 2021;31(4):1016–26.
21. Shen H, Zeng C, Wu X, Liu S, Chen X. Prognostic value of total bilirubin in patients with acute myocardial infarction A meta-analysis. Medicine. 2019;89(19):e19320. https://doi.org/10.1097/MD.0000000000019320.
22. Page MJ, McKenzie JE, Bossuyt PM, Bouton I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
23. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. 2013. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Last accessed 12 Sept 2022.
24. Beggs CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
25. DeSimonean R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
26. Borenstein M, Higgins JP, Hedges LV, Rothstein HR. Basics of meta-analysis. P2 is not an absolute measure of heterogeneity. Res Synth Methods. 2017;8:5–18. https://doi.org/10.1002/jrsm.1290.
27. Acet H, Ertş F, Akıl MA, Polat N, Aydin M, Akyüz A, et al. A novel predictor of infarct-related artery patency before percutaneous intervention and in-hospital outcomes for ST-segment elevation myocardial infarction patients: serum bilirubin level. Postepy Kardiol Interwencyjnej. 2014;10(2):91–7.
28. Agrawal BV, Sharma R. To study inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease as assessed by coronary angiography and syntax score. J Indian College Cardiol. 2015;53(3):209–13.
29. Akkoba MK, Canpolat U, Sahinarslan A, Alsansac Y, Nurkoc S, Aras D, et al. Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis. 2015;240(1):110–4.
30. Baumann S, Huseynov A, Koepp J, Jabbour C, Behnes M, Becher T, et al. Comparison of serum uric acid, bilirubin, and c-reactive protein as prognostic biomarkers of in-hospital mACE between women and men with ST-segment elevation myocardial infarction. Angiology. 2016;67(3):272–80.
31. Canpolat U, Aytemir K, Yorgun H, Hazroklan T, Kayra EB, Şahiner L, et al. Association of serum total bilirubin levels with the severity, extent and subtype of coronary atherosclerotic plaques detected by coronary CT angiography. Int J Cardiovasc Imaging. 2013;29(6):1371–9.
32. Celik T, Kaya MG, Akpek M, Yarligolus M, Sarli B, Topsakal R, et al. Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI. Angiology. 2014;65(S1):198–204.
33. Chung SR, Yang TH, Shin HC, Jin HY, Seo JS, Jang JS, et al. Initial total bilirubin and clinical outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. Circ J. 2016;80(6):1437–44.
34. Ekblom K, Marklund SL, Jansson JH, Osterman P, Hallmans G, Weinheil L, et al. Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting. Circ Cardiovasc Genet. 2010;3(4):340–7.
35. Elmohr MM, Al-Shiekh AA, Elhefnawi SB, Elamrosy MZ. Association of serum bilirubin level with clinical outcomes following primary percutaneous
intervention in patients with ST-segment elevation myocardial infarction. Tanta Med J. 2021;48:116–22.
38. Etkan A, Ikiz B, Uğurlu M, Iğ G, Seker R, Demirtaş S, et al. The role of bilirubin and its protective function against coronary heart disease. Herz. 2014;39(6):711–5.
39. Gül M, Uyarel H, Ergelen M, Akgül O, Karaca G, Turen S, et al. Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2013;111:166–71.
40. Güll H, Erdogan D, Tok D, Topçu S, Calışkan M, Ulus T, et al. High serum bilirubin concentration preserves coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol. 2005;25(11):2289–94.
41. Hamur H, Duman H, Bakır EM, Kucukcu Z, Demirfell S, Kalkan K, et al. Bilirubin Levels and Thorumbus Burden in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2016;67(6):565–70.
42. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Anterioscler Thromb Vasc Biol. 1996;16(2):250–5.
43. Huang FY, Peng Y, Huang BT, Yang Y, Pu XB, Chen SJ, et al. The correlation between serum total bilirubin and outcomes in patients with different subtypes of coronary artery disease. Clin Chim Acta. 2017;465:101–5.
44. Hunt SC, Kronenberg F, Eckfeldt JH, Hopkins PN, Myers RH, Hess G. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis. 2001;154(3):747–54.
45. Kaga MG, Sahin O, Akpeke M, Duran M, Uysal OK, Karadavut S, et al. Relation between serum total bilirubin levels and severity of coronary artery disease in patients with non-ST-segment elevation myocardial infarction. Angiology. 2014;65(3):245–9.
46. Khali T, Ibrahim WA, Elmall AAM. Serum bilirubin as a predictor of coronary artery disease severity in patients undergoing primary percutaneous coronary intervention. World J Cardiac Dis. 2019;8(9):203–27.
47. Kim HW, Choi DH, Lim L, Lee YM, Kang JT, Chae SS, et al. Usefulness of serum bilirubin levels as a biomarker for long-term clinical outcomes after percutaneous coronary intervention. Heart Vessels. 2015;30(6):728–33.
48. Kishimoto Y, Niki H, Saita E, Ibe S, Umei T, Miura K, et al. Blood levels of heme oxygenase-1 versus bilirubin in patients with coronary artery disease. Clin Chim Acta. 2020;504:30–5.
49. Kuvano T, Miura S, Shirai K, Ike A, Mori K, Shimizu T, et al. Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule. J Atheroscler Thromb. 2011;18:573–84.
50. Lai X, Fang Q, Yang L, Chen X, Wang H, Ma L, et al. Direct, indirect and total bilirubin and risk of incident coronary heart disease in the Dongfeng-Tongji cohort. Ann Med. 2018;50(1):16–25.
51. Mahabadi AA, Lehmann N, Möhlenkamp S, Kalsch H, Bauer M, Schulz R, et al. Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: the Heinz Nixdorf Recall study. Clin Res Cardiol. 2014;103(8):674–53.
52. Miranda B, Barrabés JA, Figueras J, Pineda V, Rodríguez-Palomares J, Lidón R, et al. Plasma bilirubin values on admission and ventricular remodeling after a first anterior ST-segment elevation acute myocardial infarction. JACC Basic Transl Sci. 2019;4(3):224–44.
53. Oda E, Kawai R. A possible cross-sectional association of serum total bilirubin concentration with arterial stiffness with serum bilirubin levels in established coronary artery disease. Angiology. 2014;65(4):403–10.
54. Zhang ZY, Bian LQ, Kim SJ, Zhou CC, Choi YH. Inverse relation of total serum bilirubin to coronary artery calcification score detected by multidetector computed tomography in males. Clin Cardiol. 2012;35(5):301–6.
55. Zhao X, Wang Y, Liu C, Zhou P, Sheng Z, Li J, et al. Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Front Cardiovasc Med. 2020;7:615254. https://doi.org/10.3389/fcvm.2020.615254.
56. Zhu C, Xiong Z, Zheng Z, Chen Y, Chen X, Qian X. Association of arterial stiffness with serum bilirubin levels in established coronary artery disease. Intern Med. 2012;51(16):2083–9.
57. Zhu KF, Wang YM, Wang YQ, Wang NF. The relationship between serum levels of total bilirubin and coronary plaque vulnerability. Coron Artery Dis. 2016;27(11):152–8.
58. Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology. 2004;40(4):827–35.
59. Wijnbergen I, Tijssen J, van ‘t Veer M, Michelis R, Pijls NH. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction. Catheter Cardiovasc Interv. 2013;82(3):379–84.
60. Banher M, Tafflet M, Bataille S, Escolano S, Livarak B, Foucard V, et al. Female gender is an independent predictor of in-hospital mortality after STEMI in the era of primary PCI: insights from the greater Paris area PCI Registry. EuroIntervention. 2011;6(9):1073–9.
61. Mehilli J, Kastrati A, Dirschinger J, Bollwein H, Neumann FJ, Schömig A. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA. 2000;284(14):1799–805.
62. Ndreppepa G, Mehilli J, Bollwein H, Pache J, Schömig A, Kastrati A. Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. Am J Med. 2004;117(11):830–6. https://doi.org/10.1016/j.amjmed.2002.02.014.
63. Okuhara K, Kikuta T, Ozono R, et al. Change in bilirubin level following acute myocardial infarction is an index for heme oxygenase activation. South Med J. 2010;103(9):786–81.
78. Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol. 2002;22(10):1680–5.

79. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem. 1995;41(10):1504–8.

80. Vitek L. Bilirubin as a predictor of diseases of civilization. Is it time to establish decision limits for serum bilirubin concentrations? Arch Biochem Biophys. 2019;672:108062. https://doi.org/10.1016/j.abb.2019.108062.

81. Kunutsor SK. Serum total bilirubin levels and coronary heart disease—Causal association or epiphenomenon? Exp Gerontol. 2015;72:63–6.

82. Hinds TD Jr, Stec DE. Bilirubin, a cardiometabolic signaling molecule. Hypertension. 2018;72(4):788–95.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.